Crohn’s Disease Characteristics, Current and Previous Medical Treatment, and Surgical History of CD Patients
| . | Crohn’s disease (5 + 15 cm samples) . | Crohn’s disease with stenosis (CD-S, only 5 cm sample) . |
|---|---|---|
| Number of patients, n | 44 | 7 |
| Disease duration, years (median (IQR)) | 10.0 (19.8) | 8.0 (13.0) |
| Subclassification of patients,a n (%) | ||
| CD-TIb (inflamed 5 cm, normal 15 cm) | 22 (50.0%) | 0 |
| CD-Ac (inflamed 5 cm and 15 cm) | 10 (22.7%) | 0 |
| CD-Rd (noninflamed 5 cm and 15 cm) | 12 (27.3%) | 0 |
| CD-Se (ileal stenosis 5 cm) | 0 | 7 (100%) |
| Montreal location, n (%) | ||
| Terminal ileum (L1) | 23 (52.3%) | 1 (14.3%) |
| Ileocolonic (L3) | 16 (36.4%) | 4 (57.1%) |
| Ileocolonic + Upper GI (L3 + L4) | 5 (11.4%) | 2 (28.6%) |
| Montreal behaviour, n (%) | ||
| Nonstricturing, nonpenetrating (B1) | 8 (18.2%) | 0 |
| Nonstricturing, nonpenetrating + perianal (B1p) | 2 (4.5%) | 1 (14.3%) |
| Stricturing (B2) | 15 (34.1%) | 3 (42.9%) |
| Stricturing + perianal (B2p) | 6 (13.6%) | 2 (28.6%) |
| Penetrating (B3) | 11 (25%) | 1 (14.3%) |
| Penetrating + perianal (B3p) | 2 (4.5%) | 0 |
| Montreal age (age at diagnosis), n (%) | ||
| 16 years or younger (A1) | 12 (27.3%) | 1 (14.3%) |
| 17–40 years (A2) | 22 (50%) | 5 (71.4%) |
| Over 40 years (A3) | 10 (22.7%) | 1 (14.3%) |
| CD-medication, n (%) | f | g |
| No medical therapy for CD | 18 (40.9%) | 1 (14.3) |
| Budesonide | 7 (15.9%) | 4 (57.2%) |
| Prednisolone | 4 (9.1%) | 0 |
| 5-ASA | 3 (6.8%) | 1 (14.3%) |
| Azathioprine | 6 (13.6%) | 0 |
| Methotrexate | 3 (6.8%) | 0 |
| Adalimumab | 4 (9.1%) | 2 (28.6%) |
| Infliximab | 7 (15.9%) | 1 (14.3%) |
| Vedolizumab | 1 (2.3%) | 1 (14.3%) |
| Treatment naïve, n (%) | 6 (13.6%) | 0 |
| TNFα naïve, n (%) | 23 (52.3%) | 2 (28.6%) |
| Rutgeerts score, n (%) | ||
| i0 | 12 (27.3%) | 0 |
| i1 | 12 (27.3%) | 0 |
| i2 | 5 (11.4%) | 0 |
| i3 | 6 (13.6%) | 0 |
| i4 | 9 (20.5%) | 7 (100%) |
| Ileocecal resection | 28 (63.6%) | 4 (57.1%) |
| . | Crohn’s disease (5 + 15 cm samples) . | Crohn’s disease with stenosis (CD-S, only 5 cm sample) . |
|---|---|---|
| Number of patients, n | 44 | 7 |
| Disease duration, years (median (IQR)) | 10.0 (19.8) | 8.0 (13.0) |
| Subclassification of patients,a n (%) | ||
| CD-TIb (inflamed 5 cm, normal 15 cm) | 22 (50.0%) | 0 |
| CD-Ac (inflamed 5 cm and 15 cm) | 10 (22.7%) | 0 |
| CD-Rd (noninflamed 5 cm and 15 cm) | 12 (27.3%) | 0 |
| CD-Se (ileal stenosis 5 cm) | 0 | 7 (100%) |
| Montreal location, n (%) | ||
| Terminal ileum (L1) | 23 (52.3%) | 1 (14.3%) |
| Ileocolonic (L3) | 16 (36.4%) | 4 (57.1%) |
| Ileocolonic + Upper GI (L3 + L4) | 5 (11.4%) | 2 (28.6%) |
| Montreal behaviour, n (%) | ||
| Nonstricturing, nonpenetrating (B1) | 8 (18.2%) | 0 |
| Nonstricturing, nonpenetrating + perianal (B1p) | 2 (4.5%) | 1 (14.3%) |
| Stricturing (B2) | 15 (34.1%) | 3 (42.9%) |
| Stricturing + perianal (B2p) | 6 (13.6%) | 2 (28.6%) |
| Penetrating (B3) | 11 (25%) | 1 (14.3%) |
| Penetrating + perianal (B3p) | 2 (4.5%) | 0 |
| Montreal age (age at diagnosis), n (%) | ||
| 16 years or younger (A1) | 12 (27.3%) | 1 (14.3%) |
| 17–40 years (A2) | 22 (50%) | 5 (71.4%) |
| Over 40 years (A3) | 10 (22.7%) | 1 (14.3%) |
| CD-medication, n (%) | f | g |
| No medical therapy for CD | 18 (40.9%) | 1 (14.3) |
| Budesonide | 7 (15.9%) | 4 (57.2%) |
| Prednisolone | 4 (9.1%) | 0 |
| 5-ASA | 3 (6.8%) | 1 (14.3%) |
| Azathioprine | 6 (13.6%) | 0 |
| Methotrexate | 3 (6.8%) | 0 |
| Adalimumab | 4 (9.1%) | 2 (28.6%) |
| Infliximab | 7 (15.9%) | 1 (14.3%) |
| Vedolizumab | 1 (2.3%) | 1 (14.3%) |
| Treatment naïve, n (%) | 6 (13.6%) | 0 |
| TNFα naïve, n (%) | 23 (52.3%) | 2 (28.6%) |
| Rutgeerts score, n (%) | ||
| i0 | 12 (27.3%) | 0 |
| i1 | 12 (27.3%) | 0 |
| i2 | 5 (11.4%) | 0 |
| i3 | 6 (13.6%) | 0 |
| i4 | 9 (20.5%) | 7 (100%) |
| Ileocecal resection | 28 (63.6%) | 4 (57.1%) |
aBased on endoscopic evaluation of inflammation
bCD-TI; Crohn’s disease patients with terminal ileitis
cCD-A; Crohn’s disease patients with endoscopic active inflammation
dCD-R; Crohn’s disease patients in endoscopic remission
eCD-S; Crohn’s disease patients with ileal stenosis
fComedication: n = 8 (18.2%) used 2 CD medications, n = 1 (2.3%) used 3 CD medications
gComedication: n = 3 (42.9%) used 2 CD medications, n = 0 used 3 CD medications
Crohn’s Disease Characteristics, Current and Previous Medical Treatment, and Surgical History of CD Patients
| . | Crohn’s disease (5 + 15 cm samples) . | Crohn’s disease with stenosis (CD-S, only 5 cm sample) . |
|---|---|---|
| Number of patients, n | 44 | 7 |
| Disease duration, years (median (IQR)) | 10.0 (19.8) | 8.0 (13.0) |
| Subclassification of patients,a n (%) | ||
| CD-TIb (inflamed 5 cm, normal 15 cm) | 22 (50.0%) | 0 |
| CD-Ac (inflamed 5 cm and 15 cm) | 10 (22.7%) | 0 |
| CD-Rd (noninflamed 5 cm and 15 cm) | 12 (27.3%) | 0 |
| CD-Se (ileal stenosis 5 cm) | 0 | 7 (100%) |
| Montreal location, n (%) | ||
| Terminal ileum (L1) | 23 (52.3%) | 1 (14.3%) |
| Ileocolonic (L3) | 16 (36.4%) | 4 (57.1%) |
| Ileocolonic + Upper GI (L3 + L4) | 5 (11.4%) | 2 (28.6%) |
| Montreal behaviour, n (%) | ||
| Nonstricturing, nonpenetrating (B1) | 8 (18.2%) | 0 |
| Nonstricturing, nonpenetrating + perianal (B1p) | 2 (4.5%) | 1 (14.3%) |
| Stricturing (B2) | 15 (34.1%) | 3 (42.9%) |
| Stricturing + perianal (B2p) | 6 (13.6%) | 2 (28.6%) |
| Penetrating (B3) | 11 (25%) | 1 (14.3%) |
| Penetrating + perianal (B3p) | 2 (4.5%) | 0 |
| Montreal age (age at diagnosis), n (%) | ||
| 16 years or younger (A1) | 12 (27.3%) | 1 (14.3%) |
| 17–40 years (A2) | 22 (50%) | 5 (71.4%) |
| Over 40 years (A3) | 10 (22.7%) | 1 (14.3%) |
| CD-medication, n (%) | f | g |
| No medical therapy for CD | 18 (40.9%) | 1 (14.3) |
| Budesonide | 7 (15.9%) | 4 (57.2%) |
| Prednisolone | 4 (9.1%) | 0 |
| 5-ASA | 3 (6.8%) | 1 (14.3%) |
| Azathioprine | 6 (13.6%) | 0 |
| Methotrexate | 3 (6.8%) | 0 |
| Adalimumab | 4 (9.1%) | 2 (28.6%) |
| Infliximab | 7 (15.9%) | 1 (14.3%) |
| Vedolizumab | 1 (2.3%) | 1 (14.3%) |
| Treatment naïve, n (%) | 6 (13.6%) | 0 |
| TNFα naïve, n (%) | 23 (52.3%) | 2 (28.6%) |
| Rutgeerts score, n (%) | ||
| i0 | 12 (27.3%) | 0 |
| i1 | 12 (27.3%) | 0 |
| i2 | 5 (11.4%) | 0 |
| i3 | 6 (13.6%) | 0 |
| i4 | 9 (20.5%) | 7 (100%) |
| Ileocecal resection | 28 (63.6%) | 4 (57.1%) |
| . | Crohn’s disease (5 + 15 cm samples) . | Crohn’s disease with stenosis (CD-S, only 5 cm sample) . |
|---|---|---|
| Number of patients, n | 44 | 7 |
| Disease duration, years (median (IQR)) | 10.0 (19.8) | 8.0 (13.0) |
| Subclassification of patients,a n (%) | ||
| CD-TIb (inflamed 5 cm, normal 15 cm) | 22 (50.0%) | 0 |
| CD-Ac (inflamed 5 cm and 15 cm) | 10 (22.7%) | 0 |
| CD-Rd (noninflamed 5 cm and 15 cm) | 12 (27.3%) | 0 |
| CD-Se (ileal stenosis 5 cm) | 0 | 7 (100%) |
| Montreal location, n (%) | ||
| Terminal ileum (L1) | 23 (52.3%) | 1 (14.3%) |
| Ileocolonic (L3) | 16 (36.4%) | 4 (57.1%) |
| Ileocolonic + Upper GI (L3 + L4) | 5 (11.4%) | 2 (28.6%) |
| Montreal behaviour, n (%) | ||
| Nonstricturing, nonpenetrating (B1) | 8 (18.2%) | 0 |
| Nonstricturing, nonpenetrating + perianal (B1p) | 2 (4.5%) | 1 (14.3%) |
| Stricturing (B2) | 15 (34.1%) | 3 (42.9%) |
| Stricturing + perianal (B2p) | 6 (13.6%) | 2 (28.6%) |
| Penetrating (B3) | 11 (25%) | 1 (14.3%) |
| Penetrating + perianal (B3p) | 2 (4.5%) | 0 |
| Montreal age (age at diagnosis), n (%) | ||
| 16 years or younger (A1) | 12 (27.3%) | 1 (14.3%) |
| 17–40 years (A2) | 22 (50%) | 5 (71.4%) |
| Over 40 years (A3) | 10 (22.7%) | 1 (14.3%) |
| CD-medication, n (%) | f | g |
| No medical therapy for CD | 18 (40.9%) | 1 (14.3) |
| Budesonide | 7 (15.9%) | 4 (57.2%) |
| Prednisolone | 4 (9.1%) | 0 |
| 5-ASA | 3 (6.8%) | 1 (14.3%) |
| Azathioprine | 6 (13.6%) | 0 |
| Methotrexate | 3 (6.8%) | 0 |
| Adalimumab | 4 (9.1%) | 2 (28.6%) |
| Infliximab | 7 (15.9%) | 1 (14.3%) |
| Vedolizumab | 1 (2.3%) | 1 (14.3%) |
| Treatment naïve, n (%) | 6 (13.6%) | 0 |
| TNFα naïve, n (%) | 23 (52.3%) | 2 (28.6%) |
| Rutgeerts score, n (%) | ||
| i0 | 12 (27.3%) | 0 |
| i1 | 12 (27.3%) | 0 |
| i2 | 5 (11.4%) | 0 |
| i3 | 6 (13.6%) | 0 |
| i4 | 9 (20.5%) | 7 (100%) |
| Ileocecal resection | 28 (63.6%) | 4 (57.1%) |
aBased on endoscopic evaluation of inflammation
bCD-TI; Crohn’s disease patients with terminal ileitis
cCD-A; Crohn’s disease patients with endoscopic active inflammation
dCD-R; Crohn’s disease patients in endoscopic remission
eCD-S; Crohn’s disease patients with ileal stenosis
fComedication: n = 8 (18.2%) used 2 CD medications, n = 1 (2.3%) used 3 CD medications
gComedication: n = 3 (42.9%) used 2 CD medications, n = 0 used 3 CD medications
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
